The high price target for VTGN is … 3 equities research analysts have issued 1-year price objectives for Vistagen Therapeutics' stock. Find the latest VistaGen Therapeutics, Inc. (VTGN) stock quote, history, news and other vital information to help you with your stock trading and investing. View our full suite of financial calendars and market data tables, all for free.Receive a free world-class investing education from MarketBeat. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Dow Jones, a News Corp company News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services VistaGen Therapeutics stock price target cut to $4 from $6 at Maxim Group Jul. VTGN updated stock price target summary. The lighter blue line represents the stock's consensus price target. The dark blue line represents the company's actual price. Now is the time for investors to get positioned for gains. Its portfolio focuses on three clinical-stage product; neuropathic pain (NP), levodopa-induced dyskinesia (LID), social anxiety disorder (SAD) and suicidal ideation (SI). View which stocks are hot on social media with MarketBeat's trending stocks report.Identify stocks that meet your criteria using seven unique stock screeners. All rights reserved. Learn everything you need to know about successful options trading with this three-part video course.Looking for new stock ideas? Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Its product include AV-101 product and PH10 neuroactive nasal spray.The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA. On average, they expect Vistagen Therapeutics' stock price to reach $0.85 in the next twelve months. 3 Wall Street analysts have issued ratings and price targets for Vistagen Therapeutics in the last 12 months.